Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model

The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2025-01, Vol.20 (1), p.e0312369
Hauptverfasser: Fraysse, Jeremy, Anderson, Sarah-Jane, Smith, Justin C, Matthews, Derrick D, Sarkar, Supriya, de Aragao, Filipa, Blissett, Rob
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page e0312369
container_title PloS one
container_volume 20
creator Fraysse, Jeremy
Anderson, Sarah-Jane
Smith, Justin C
Matthews, Derrick D
Sarkar, Supriya
de Aragao, Filipa
Blissett, Rob
description The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV. The Georgia Department of Public Health has set an ambitious 25% HIV incidence reduction target, which could be reached with a daily-oral PrEP coverage of 42.2%. However, the target could be achieved at lower levels of PrEP coverage (34.6%) if a mix of PrEP modalities was used, such as an equal split of long-acting CAB PrEP and daily-oral PrEP. Our results clearly demonstrate that broadening access to new PrEP options has the potential to facilitate the achievement of public health HIV incidence reduction goals at plausible levels of PrEP coverage.
doi_str_mv 10.1371/journal.pone.0312369
format Article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3153511202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A822931383</galeid><doaj_id>oai_doaj_org_article_ed60e70360764e868d6a79fc6aeb3119</doaj_id><sourcerecordid>A822931383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4879-552749cd0decde896b1f4c581a7b93ce5d7b78dddacea5053b4b8bd215a2404b3</originalsourceid><addsrcrecordid>eNqNk81u1DAQxyMEoqXwBggsIRAcdrHjJE64oFUF7UqVKvHRqzWxJ4mrJN7aTrt9OZ4Nb7utuqgHFClxxr_5z3jGkySvGZ0zLtjnczu5Efr5yo44p5ylvKieJPus4umsSCl_-mC9l7zw_pzSnJdF8TzZ45UoBaNsP_mzUJ3BSzO2JHRIfICAxDbkCK1rDZA0f0-Ol2fEjMpoHBUSh3pSwdiRBHAtBgKDjd4DjuSqs6SDyyiDa3JlQndjNSNZhB7GADGEs1PbEVyvYNSoyeRvog1TH8xgNfRk5XAWt62fHMYfu-que1gb_4UsyAAxx_gyKoIRx_5l8qyB3uOr7fcg-f3926_D49nJ6dHycHEyU1kpqlmepyKrlKYalcayKmrWZCovGYi64gpzLWpRaq1BIeSxTHVWl7VOWQ5pRrOaHyRvb3VXvfVyW3ovOct5zlhK00gsbwlt4VyunBnAXUsLRt4YYjUluJh5jxJ1QVFQXlBRZFgWpS5AVI0qAGvOYtMOkq_baFM9oFY4Bgf9jujuzmg62dpLyZhgIhVlVPi4VXD2YkIf5GC8wj62Ae20SbygVUpFziL67h_08eNtqRbiCczY2BhYbUTlokzTijNe8kjNH6Hio3EwKl7UxkT7jsOnHYfIBFyHFibv5fLnj_9nT8922Q8P2A6hD523_bS5t34XzG5B5az3Dpv7KjMqN3N2Vw25mTO5nbPo9uZhh-6d7gaL_wXhdiVo</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3153511202</pqid></control><display><type>article</type><title>Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Fraysse, Jeremy ; Anderson, Sarah-Jane ; Smith, Justin C ; Matthews, Derrick D ; Sarkar, Supriya ; de Aragao, Filipa ; Blissett, Rob</creator><creatorcontrib>Fraysse, Jeremy ; Anderson, Sarah-Jane ; Smith, Justin C ; Matthews, Derrick D ; Sarkar, Supriya ; de Aragao, Filipa ; Blissett, Rob</creatorcontrib><description>The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV. The Georgia Department of Public Health has set an ambitious 25% HIV incidence reduction target, which could be reached with a daily-oral PrEP coverage of 42.2%. However, the target could be achieved at lower levels of PrEP coverage (34.6%) if a mix of PrEP modalities was used, such as an equal split of long-acting CAB PrEP and daily-oral PrEP. Our results clearly demonstrate that broadening access to new PrEP options has the potential to facilitate the achievement of public health HIV incidence reduction goals at plausible levels of PrEP coverage.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0312369</identifier><identifier>PMID: 39787101</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Adaptation ; Adult ; African Americans ; AIDS ; Anti-HIV Agents - administration &amp; dosage ; Anti-HIV Agents - therapeutic use ; Biology and Life Sciences ; Demographics ; Diketopiperazines ; Disease prevention ; Disease transmission ; Estimates ; Gays &amp; lesbians ; Georgia - epidemiology ; Health aspects ; Health surveillance ; Hispanic Americans ; HIV ; HIV infection ; HIV Infections - epidemiology ; HIV Infections - prevention &amp; control ; Homosexuality, Male ; Human immunodeficiency virus ; Humans ; Incidence ; Male ; Mathematical models ; Medicine and Health Sciences ; Mens health ; Models, Theoretical ; MSM (Men who have sex with men) ; People and Places ; Pre-Exposure Prophylaxis - methods ; Prevention ; Prophylaxis ; Public health ; Pyridones - administration &amp; dosage ; Pyridones - therapeutic use ; Sexually transmitted diseases ; Statistics ; STD</subject><ispartof>PloS one, 2025-01, Vol.20 (1), p.e0312369</ispartof><rights>Copyright: © 2025 Fraysse et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2025 Public Library of Science</rights><rights>2025 Fraysse et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2025 Fraysse et al 2025 Fraysse et al</rights><rights>2025 Fraysse et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4879-552749cd0decde896b1f4c581a7b93ce5d7b78dddacea5053b4b8bd215a2404b3</cites><orcidid>0000-0002-7608-1391</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717278/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717278/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39787101$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fraysse, Jeremy</creatorcontrib><creatorcontrib>Anderson, Sarah-Jane</creatorcontrib><creatorcontrib>Smith, Justin C</creatorcontrib><creatorcontrib>Matthews, Derrick D</creatorcontrib><creatorcontrib>Sarkar, Supriya</creatorcontrib><creatorcontrib>de Aragao, Filipa</creatorcontrib><creatorcontrib>Blissett, Rob</creatorcontrib><title>Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV. The Georgia Department of Public Health has set an ambitious 25% HIV incidence reduction target, which could be reached with a daily-oral PrEP coverage of 42.2%. However, the target could be achieved at lower levels of PrEP coverage (34.6%) if a mix of PrEP modalities was used, such as an equal split of long-acting CAB PrEP and daily-oral PrEP. Our results clearly demonstrate that broadening access to new PrEP options has the potential to facilitate the achievement of public health HIV incidence reduction goals at plausible levels of PrEP coverage.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adaptation</subject><subject>Adult</subject><subject>African Americans</subject><subject>AIDS</subject><subject>Anti-HIV Agents - administration &amp; dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Biology and Life Sciences</subject><subject>Demographics</subject><subject>Diketopiperazines</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>Estimates</subject><subject>Gays &amp; lesbians</subject><subject>Georgia - epidemiology</subject><subject>Health aspects</subject><subject>Health surveillance</subject><subject>Hispanic Americans</subject><subject>HIV</subject><subject>HIV infection</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - prevention &amp; control</subject><subject>Homosexuality, Male</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Mathematical models</subject><subject>Medicine and Health Sciences</subject><subject>Mens health</subject><subject>Models, Theoretical</subject><subject>MSM (Men who have sex with men)</subject><subject>People and Places</subject><subject>Pre-Exposure Prophylaxis - methods</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>Public health</subject><subject>Pyridones - administration &amp; dosage</subject><subject>Pyridones - therapeutic use</subject><subject>Sexually transmitted diseases</subject><subject>Statistics</subject><subject>STD</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk81u1DAQxyMEoqXwBggsIRAcdrHjJE64oFUF7UqVKvHRqzWxJ4mrJN7aTrt9OZ4Nb7utuqgHFClxxr_5z3jGkySvGZ0zLtjnczu5Efr5yo44p5ylvKieJPus4umsSCl_-mC9l7zw_pzSnJdF8TzZ45UoBaNsP_mzUJ3BSzO2JHRIfICAxDbkCK1rDZA0f0-Ol2fEjMpoHBUSh3pSwdiRBHAtBgKDjd4DjuSqs6SDyyiDa3JlQndjNSNZhB7GADGEs1PbEVyvYNSoyeRvog1TH8xgNfRk5XAWt62fHMYfu-que1gb_4UsyAAxx_gyKoIRx_5l8qyB3uOr7fcg-f3926_D49nJ6dHycHEyU1kpqlmepyKrlKYalcayKmrWZCovGYi64gpzLWpRaq1BIeSxTHVWl7VOWQ5pRrOaHyRvb3VXvfVyW3ovOct5zlhK00gsbwlt4VyunBnAXUsLRt4YYjUluJh5jxJ1QVFQXlBRZFgWpS5AVI0qAGvOYtMOkq_baFM9oFY4Bgf9jujuzmg62dpLyZhgIhVlVPi4VXD2YkIf5GC8wj62Ae20SbygVUpFziL67h_08eNtqRbiCczY2BhYbUTlokzTijNe8kjNH6Hio3EwKl7UxkT7jsOnHYfIBFyHFibv5fLnj_9nT8922Q8P2A6hD523_bS5t34XzG5B5az3Dpv7KjMqN3N2Vw25mTO5nbPo9uZhh-6d7gaL_wXhdiVo</recordid><startdate>20250109</startdate><enddate>20250109</enddate><creator>Fraysse, Jeremy</creator><creator>Anderson, Sarah-Jane</creator><creator>Smith, Justin C</creator><creator>Matthews, Derrick D</creator><creator>Sarkar, Supriya</creator><creator>de Aragao, Filipa</creator><creator>Blissett, Rob</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7608-1391</orcidid></search><sort><creationdate>20250109</creationdate><title>Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model</title><author>Fraysse, Jeremy ; Anderson, Sarah-Jane ; Smith, Justin C ; Matthews, Derrick D ; Sarkar, Supriya ; de Aragao, Filipa ; Blissett, Rob</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4879-552749cd0decde896b1f4c581a7b93ce5d7b78dddacea5053b4b8bd215a2404b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adaptation</topic><topic>Adult</topic><topic>African Americans</topic><topic>AIDS</topic><topic>Anti-HIV Agents - administration &amp; dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Biology and Life Sciences</topic><topic>Demographics</topic><topic>Diketopiperazines</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>Estimates</topic><topic>Gays &amp; lesbians</topic><topic>Georgia - epidemiology</topic><topic>Health aspects</topic><topic>Health surveillance</topic><topic>Hispanic Americans</topic><topic>HIV</topic><topic>HIV infection</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - prevention &amp; control</topic><topic>Homosexuality, Male</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Mathematical models</topic><topic>Medicine and Health Sciences</topic><topic>Mens health</topic><topic>Models, Theoretical</topic><topic>MSM (Men who have sex with men)</topic><topic>People and Places</topic><topic>Pre-Exposure Prophylaxis - methods</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>Public health</topic><topic>Pyridones - administration &amp; dosage</topic><topic>Pyridones - therapeutic use</topic><topic>Sexually transmitted diseases</topic><topic>Statistics</topic><topic>STD</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fraysse, Jeremy</creatorcontrib><creatorcontrib>Anderson, Sarah-Jane</creatorcontrib><creatorcontrib>Smith, Justin C</creatorcontrib><creatorcontrib>Matthews, Derrick D</creatorcontrib><creatorcontrib>Sarkar, Supriya</creatorcontrib><creatorcontrib>de Aragao, Filipa</creatorcontrib><creatorcontrib>Blissett, Rob</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fraysse, Jeremy</au><au>Anderson, Sarah-Jane</au><au>Smith, Justin C</au><au>Matthews, Derrick D</au><au>Sarkar, Supriya</au><au>de Aragao, Filipa</au><au>Blissett, Rob</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2025-01-09</date><risdate>2025</risdate><volume>20</volume><issue>1</issue><spage>e0312369</spage><pages>e0312369-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The US faces substantial demographic and geographic disparities in both HIV burden and access to pre-exposure prophylaxis (PrEP), an effective strategy to prevent HIV acquisition. Long-acting cabotegravir (CAB) is a novel, injectable PrEP option which demonstrated superior reduction in risk of HIV acquisition compared to daily-oral PrEP in the HPTN083 trial. We modelled the impact of increased PrEP initiations and the introduction of long-acting CAB on HIV incidence among men who have sex with men (MSM) in Atlanta, Georgia, a population with a high burden of HIV. The Georgia Department of Public Health has set an ambitious 25% HIV incidence reduction target, which could be reached with a daily-oral PrEP coverage of 42.2%. However, the target could be achieved at lower levels of PrEP coverage (34.6%) if a mix of PrEP modalities was used, such as an equal split of long-acting CAB PrEP and daily-oral PrEP. Our results clearly demonstrate that broadening access to new PrEP options has the potential to facilitate the achievement of public health HIV incidence reduction goals at plausible levels of PrEP coverage.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39787101</pmid><doi>10.1371/journal.pone.0312369</doi><tpages>e0312369</tpages><orcidid>https://orcid.org/0000-0002-7608-1391</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2025-01, Vol.20 (1), p.e0312369
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_3153511202
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS)
subjects Acquired immune deficiency syndrome
Adaptation
Adult
African Americans
AIDS
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Biology and Life Sciences
Demographics
Diketopiperazines
Disease prevention
Disease transmission
Estimates
Gays & lesbians
Georgia - epidemiology
Health aspects
Health surveillance
Hispanic Americans
HIV
HIV infection
HIV Infections - epidemiology
HIV Infections - prevention & control
Homosexuality, Male
Human immunodeficiency virus
Humans
Incidence
Male
Mathematical models
Medicine and Health Sciences
Mens health
Models, Theoretical
MSM (Men who have sex with men)
People and Places
Pre-Exposure Prophylaxis - methods
Prevention
Prophylaxis
Public health
Pyridones - administration & dosage
Pyridones - therapeutic use
Sexually transmitted diseases
Statistics
STD
title Achieving the state of Georgia 25% HIV incidence reduction target among men who have sex with men in Atlanta through expanded use of multimodal pre-exposure prophylaxis: A mathematical model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T17%3A30%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Achieving%20the%20state%20of%20Georgia%2025%25%20HIV%20incidence%20reduction%20target%20among%20men%20who%20have%20sex%20with%20men%20in%20Atlanta%20through%20expanded%20use%20of%20multimodal%20pre-exposure%20prophylaxis:%20A%20mathematical%20model&rft.jtitle=PloS%20one&rft.au=Fraysse,%20Jeremy&rft.date=2025-01-09&rft.volume=20&rft.issue=1&rft.spage=e0312369&rft.pages=e0312369-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0312369&rft_dat=%3Cgale_plos_%3EA822931383%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3153511202&rft_id=info:pmid/39787101&rft_galeid=A822931383&rft_doaj_id=oai_doaj_org_article_ed60e70360764e868d6a79fc6aeb3119&rfr_iscdi=true